1
|
Adeno-Associated Vector-Delivered CRISPR/ SaCas9 System Reduces Feline Leukemia Virus Production In Vitro. Viruses 2021; 13:v13081636. [PMID: 34452500 PMCID: PMC8402633 DOI: 10.3390/v13081636] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Revised: 08/12/2021] [Accepted: 08/14/2021] [Indexed: 12/16/2022] Open
Abstract
Feline leukemia virus (FeLV) is a retrovirus of cats worldwide. High viral loads are associated with progressive infection and the death of the host, due to FeLV-associated disease. In contrast, low viral loads, an effective immune response, and a better clinical outcome can be observed in cats with regressive infection. We hypothesize that by lowering viral loads in progressively infected cats, using CRISPR/SaCas9-assisted gene therapy, the cat’s immune system may be permitted to direct the infection towards a regressive outcome. In a step towards this goal, the present study evaluates different adeno-associated vectors (AAVs) for their competence in delivering a gene editing system into feline cells, followed by investigations of the CRISPR/SaCas9 targeting efficiency for different sites within the FeLV provirus. Nine natural AAV serotypes, two AAV hybrid strains, and Anc80L65, an in silico predicted AAV ancestor, were tested for their potential to infect different feline cell lines and feline primary cells. AAV-DJ revealed superior infection efficiency and was thus employed in subsequent transduction experiments. The introduction of double-strand breaks, using the CRISPR/SaCas9 system targeting 12 selected FeLV provirus sites, was confirmed by T7 endonuclease 1 (T7E1), as well as Tracking of Indels by Decomposition (TIDE) analysis. The highest percentage (up to 80%) of nonhomologous end-joining (NHEJ) was found in the highly conserved gag and pol regions. Subsequent transduction experiments, using AAV-DJ, confirmed indel formation and showed a significant reduction in FeLV p27 antigen for some targets. The targeting of the FeLV provirus was efficient when using the CRISPR/SaCas9 approach in vitro. Whether the observed extent of provirus targeting will be sufficient to provide progressively FeLV-infected cats with the means to overcome the infection needs to be further investigated in vivo.
Collapse
|
2
|
Hammett TM, Bronson RT. Unrecognized "AIDS" in Monkeys, 1969-1980: Explanations and Implications. Am J Public Health 2016; 106:1015-22. [PMID: 27077355 PMCID: PMC4880232 DOI: 10.2105/ajph.2016.303085] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/16/2016] [Indexed: 11/04/2022]
Abstract
AIDS was recognized in humans in 1981 and a simian form was described in the years 1983 to 1985. However, beginning in the late 1960s, outbreaks of opportunistic infections of AIDS were seen in monkeys in the United States. This apparent syndrome went unrecognized at the time. We have assembled those early cases in monkeys and offer reasons why they did not result in earlier recognition of simian or human AIDS, including weaknesses in understanding disease mechanisms, absence of evidence of human retroviruses, and a climate of opinion that devalued investigation of infectious disease and immunologic origins of disease. The "epistemological obstacle" explains important elements of this history in that misconceptions blocked understanding of the dependent relationship among viral infection, immunodeficiency, and opportunistic diseases. Had clearer understanding of the evidence from monkeys allowed human AIDS to be recognized earlier, life-saving prevention and treatment interventions might have been implemented sooner.
Collapse
Affiliation(s)
- Theodore M Hammett
- Theodore M. Hammett is with Abt Associates, Cambridge, MA. Roderick T. Bronson is with Harvard Medical School, Boston, MA
| | - Roderick T Bronson
- Theodore M. Hammett is with Abt Associates, Cambridge, MA. Roderick T. Bronson is with Harvard Medical School, Boston, MA
| |
Collapse
|
3
|
Helfer-Hungerbuehler AK, Widmer S, Kessler Y, Riond B, Boretti FS, Grest P, Lutz H, Hofmann-Lehmann R. Long-term follow up of feline leukemia virus infection and characterization of viral RNA loads using molecular methods in tissues of cats with different infection outcomes. Virus Res 2015; 197:137-50. [DOI: 10.1016/j.virusres.2014.12.025] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2014] [Revised: 12/18/2014] [Accepted: 12/19/2014] [Indexed: 10/24/2022]
|
4
|
Feline leukaemia virus: Half a century since its discovery. Vet J 2013; 195:16-23. [DOI: 10.1016/j.tvjl.2012.07.004] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2012] [Revised: 06/27/2012] [Accepted: 07/04/2012] [Indexed: 11/30/2022]
|
5
|
Abstract
Our understanding of the pathogenesis of FeLV infection is little changed from what was described by Hardy and his colleagues in the mid-1970s. The prevention of FeLV infection consists, first, of avoiding the agent and, second, of providing optimum immunologic resistance. In multi-cat environments, the former is achieved through test-and-removal methods perennially reviewed in the literature and by minimizing exposure to outdoor cats. The latter is possible by attempting to maintain a low-stress, pathogen-free household and by the use of appropriate, effective immunization programs. Simple immunologic concepts used for the development of vaccines against feline distemper and rabies have evolved to enable generation of products that can now protect against retroviruses. The use of more complex biologic methods, such as recombinant technology and the manipulation of antigen presentation, bears encouragement, so that perhaps one day the most destructive of feline infectious diseases may be checked.
Collapse
Affiliation(s)
- A S Loar
- Professional Animal Laboratories, Irvine, California
| |
Collapse
|
6
|
Affiliation(s)
- S M Cotter
- Department of Medicine, Tufts University School of Veterinary Medicine, North Grafton, Massachusetts 01536
| |
Collapse
|
7
|
Abstract
Feline leukaemia virus (FeLV) usually occurs in its natural species, the domestic cat. FeLV is also important to human individuals as a comparative model, as it may cause a variety of diseases, some malignant and some benign, such as immunosuppression, which bears a resemblance to AIDS (acquired immune deficiency syndrome) in man. FeLV is transmitted among cats by contagion. The main sources of infection are persistently infected carrier cats which continuously excrete virus. Dissemination of FeLV among cats may be prevented by identifying infected carrier cats and removing them from contact with non-infected cats. Removal programmes using indirect immunofluorescence antibody tests were applied successfully in The Netherlands. The proportion of FeLV-positive cats decreased from 9% in 1974 to approximately 3% in 1985 during such a programme. The results of a removal programme carried out in a catbreeders' society were even better: the incidence of cats positive for FeLV decreased from 11% in 1974 to less than 2% within 4 years. None of the cats tested in this society has been found to be positive for FeLV since 1984. Besides removal programmes, other methods of control, such as pre-exposure treatment, were developed to prevent the spread of FeLV. We attempted to protect kittens against oronasal infection with FeLV by treatment with virus-neutralizing (VN) monoclonal antibodies (MoAbs) directed against an epitope on the viral glycoprotein gp70. However, no protection was achieved. It is unlikely that the amount of VN antibodies, the mode and route of their application or the infectious dose of FeLV used can account for this failure. Other possible explanations for the lack of protective effect are that (i) the restricted epitope specificity of the MoAb preparation used may have led to selection of neutralization-resistant virus mutants, or (ii) other mechanisms than virus neutralization (complement-mediated lysis, antibody-dependent cell cytotoxicity), that may be involved in protection, function less efficiently with MoAb. However, in the light of our finding that an early anti-idiotypic response is observed in all cats following administration of the MoAb preparation, the rapid clearance of anti-FeLV MoAb from the circulation is a more likely explanation. Efforts were further made to develop a vaccine for controlling FeLV infection. The immunostimulating complex vaccine (FeLV-ISCOM vaccine), a subunit vaccine in which FeLV gp70 is presented in a particular manner, looks promising. The protective effect of FeLV-ISCOM vaccine was studied by vaccinating six 8-week-old SPF cats with ISCOM, followed by oronasal challenge with FeLV.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- K Weijer
- The Netherlands Cancer Institute, Division of Immunology, Amsterdam
| | | | | |
Collapse
|
8
|
Bittle JL, Muir S. Vaccines produced by conventional means to control major infectious diseases of man and animals. ADVANCES IN VETERINARY SCIENCE AND COMPARATIVE MEDICINE 1989; 33:1-63. [PMID: 2648772 PMCID: PMC7150235 DOI: 10.1016/b978-0-12-039233-9.50005-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
This chapter reviews the development of some of vaccines and their use in controlling such major diseases as diphtheria, rinderpest, Newcastle disease, smallpox, pertussis, yellow fever, rabies, etc. Park–Williams Number 8 (PW8) strain is used to make diphtherial toxoid for vaccines. As a source of toxin, it is rendered nontoxic by incubation with formalin under alkaline conditions. The product's retention of antigenicity, enabling it to induce antitoxin antibodies, makes it an excellent pediatric vaccine. Vaccine against Rinderpest Virus was developed by Koch in 1897 by administering bile from infected cattle. Animals that survived were permanently immune. Formalin- and chloroform-inactivated vaccines were developed using tissues from the infected animals. For the control of Newcastle disease, a number of attenuated live-virus vaccines have been developed which are widely used to control the disease. The Bl strain, the LaSota strain, and the F strain are used to immunize birds of all ages by different routes, including by addition to drinking water and by spraying. Protection against rabies correlates with SN antibody, which can be assessed by a number of tests. Pasteur's classical vaccine, developed from infected spinal cord tissue dried at room temperature for 3–14 days, was given in a series of 21–28 inoculations beginning with material dried the longest and progressing through material dried for only 3 days.
Collapse
Affiliation(s)
- J L Bittle
- Johnson and Johnson Biotechnology Center, San Diego, California
| | | |
Collapse
|
9
|
Rojko J, Essex M, Trainin Z. Feline leukemia/sarcoma viruses and immunodeficiency. ADVANCES IN VETERINARY SCIENCE AND COMPARATIVE MEDICINE 1988; 32:57-96. [PMID: 2847504 PMCID: PMC7271325 DOI: 10.1016/b978-0-12-039232-2.50007-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
This chapter discusses the structure feline leukemia virus (FeLV) and pathogenesis of lymphomas and leukemias BY FeLV. FeLV is quite similar to the better-studied murine leukemia viruses in structure and genetic map. The virus particles bud from cytoplasmic membranes into either extracellular spaces or into vacuoles. FeLV has long been considered a typical noncytopathogenic, longlatency leukemia virus based on its behavior in fibroblasts in vitro . Recent evidence suggests that its in vivo behavior in critical target hemolymphatic tissues is as likely to be cytopathic as transforming. The type of FeLV-related disease that occurs and the disease-free interval probably are influenced by viral envelope proteins and glycoproteins and the consequences of proviral integration. FeLV subgroup specificity apparently determines when and what type of disease will occur. The ecotropic FeLV-A is the most frequent subgroup found in pet cats and is transmitted contagiously. Immunosuppression is the most frequent and the most devastating manifestation of FeLV viremia in clinical and experimental studies. It seems that multiple cell types and multiple processes are involved in the development of feline retrovirus-induced immunosuppression. Although no solid evidence is available for the malfunctioning of cat T helper cells because of the paucity of T-cell specific markers, the circumstantial evidence provided thus far indicates an impaired T helper function in FeLV-infected cats similar to that observed in humans infected with HIV. Studies on the pathogenesis of FeLV-induced immunosuppression might provide a valuable mode for a better understanding and means of control of human AIDS.
Collapse
Affiliation(s)
- J Rojko
- Veterinary Pathobiology, College of Veterinary Medicine, Ohio State University, Columbus 43210
| | | | | |
Collapse
|
10
|
Pedersen NC, Johnson L, Birch D, Theilen GH. Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective. Vet Immunol Immunopathol 1986; 11:123-48. [PMID: 3008409 PMCID: PMC7125533 DOI: 10.1016/0165-2427(86)90093-0] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Kittens immunized with purified native FeLV-gp70 or -gp85 envelope proteins developed ELISA, but not virus neutralizing, antibodies in their serum to both whole FeLV and FeLV-gp70. Kittens vaccinated with envelope proteins and infected with feline sarcoma virus (FeSV) developed smaller tumors than nonvaccinates, but a greater incidence of persistent retroviremia. Similarly, FeLV-gp70 and -gp85 vaccinated kittens were more apt to become persistently retroviremic following virulent FeLV challenge exposure than nonvaccinates. Kittens vaccinated with inactivated whole FeLV developed smaller tumors after FeSV inoculation and had a lower incidence of persistent retroviremia than nonvaccinates. The protective effect of inactivated whole FeLV vaccine against persistent retroviremia was also seen with FeLV challenge-exposed cats. Protection afforded by inactivated whole FeLV vaccine was not associated with virus neutralizing antibodies, although ELISA antibodies to both whole FeLV and FeLV-gp70 were induced by vaccination.
Collapse
|
11
|
Luciw P, Parkes D, Van Nest G, Dina D, Hendrix K, Gardner MB. Recombinant DNA approaches to feline leukemia virus immunization. BASIC LIFE SCIENCES 1986; 37:207-15. [PMID: 3010935 DOI: 10.1007/978-1-4684-5110-8_18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
We have utilized 2 recombinant DNA strategies for immunization against FeLV in cats: (a) modified live virus was attenuated by mutation and recombination, and (b) an immunogen, consisting of subunit envelope protein, was prepared in genetically engineered yeast. Results indicated that the genetically manipulated live virus preparations were not protective against FeLV challenge because they were either not attenuated in virulence or were not sufficiently antigenic. Immunization with yeast-synthesized FeLV envelope protein followed by the modified live virus gave protective immunity in cats under experimental conditions. Future immunization attempts will concentrate on enhancing the immunogenic potency of the yeast- synthesized FeLV envelope protein.
Collapse
|
12
|
Abstract
This is the second of two papers describing the biology of the naturally occurring RNA tumor viruses (oncoviruses). It will appear in two parts. In the first paper [Cancer Investigation 1(1):67-83 (1983)] the general properties of this class of viruses and the biology of the retroviruses of the "lower" vertebrates was discussed. In this paper the oncoviruses of the "higher" animals are described. Part one deals with cat retroviruses.
Collapse
|
13
|
|
14
|
|
15
|
Log T, Chang KS. Enzyme immunoassay for feline oncornavirus-associated cell membrane antigen (FOCMA) and detection of FOCMA in cell extract by enzyme immunoassay inhibition test. J Immunol Methods 1979; 26:291-303. [PMID: 221593 DOI: 10.1016/0022-1759(79)90254-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
An enzyme immunoassay (EIA) for FOCMA has been developed. The assay uses alkaline phosphatase-conjugated rabbit anti-cat IgG as the second antibody and p-nitrophenyl phosphate as the substrate for the enzyme to detect cat FOCMA antibody bound to the target cells. In comparison with the indirect immunofluorescence (IIF) test, which was originally used for FOCMA assay, our results showed a good correlation between the two methods. The EIA gives a more objective measure of FOCMA reactivity than does IIF. FOCMA was successfully extracted from FOCMA-positive cell membranes by 0.5% Triton X-100 and further fractionated by ammonium sulfate. The FOCMA activity was assayed by IIF and EIA inhibition test. Most of the FOCMA activity was found in the fractions precipitated by 30% and 50% ammonium sulfate saturation.
Collapse
|
16
|
Parodi AL. [Feline leukemia: recent developments on the causes and immunoprevention of the disease (author's transl)]. Comp Immunol Microbiol Infect Dis 1978; 1:21-30. [PMID: 230008 DOI: 10.1016/0147-9571(78)90006-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
17
|
Roberts JA. Immunotherapy in the treatment of cancer. Scott Med J 1977; 22:320-30. [PMID: 337486 DOI: 10.1177/003693307702200425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
This article is a review of immunotherapy in the treatment of cancer incorporating the history of immunotherapy in the nineteenth and twentieth centuries, assessment of the techniques currently in use and of possible future developments. Although immunotherapy is not established as a therapeutic technique, evidence suggests that the immune response does influence the development of neoplastic cells. A better understanding of the immune response and its control may lead to the production of efficacious immunological treatment of certain cancers.
Collapse
|
18
|
Essex M. Immunity to leukemia, lymphoma, and fibrosarcoma in cats: a case for immunosurveillance. CONTEMPORARY TOPICS IN IMMUNOBIOLOGY 1977; 6:71-106. [PMID: 194751 DOI: 10.1007/978-1-4684-3051-6_2] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
19
|
Weijer K, Daams JH. The presence of leukaemia (lymphosarcoma) and feline leukaemia virus (FeLv) in cats in The Netherlands. J Small Anim Pract 1976; 17:649-59. [PMID: 185459 DOI: 10.1111/j.1748-5827.1976.tb06925.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
20
|
Jarrett W, Jarrett O, Mackey L, Laird H, Hood C, Hay D. Vaccination against feline leukaemia virus using a cell membrane antigen system. Int J Cancer 1975; 16:134-41. [PMID: 170211 DOI: 10.1002/ijc.2910160115] [Citation(s) in RCA: 33] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Cats inoculated with live feline lymphoblastoid cells of the FL74 line developed high titres of antibody to feline oncornavirus-associated cell membrane antigen (FOCMA). Eight cats were subsequently challenged with a large dose of feline leukaemia virus (FeLV) of a highly pathogenic strain. All resisted infection while 10 cats given the challenge virus alone became infected. The FeLV produced by FL74 cells was shown to be of extremely low infectivity in cats and in cultured feline cells. Cats inoculated with either FL74 cells or virus purified from them did not become infected. The purified virus did not induce FOCMA antibody in cats not previously exposed to FeLV. The fact that FL74 cells are highly immunogenic, but produce virus of low infectivity, is of value in devising vaccines against FeLV. Cats were also inoculated with FL74 cells which had been inactivated with paraformaldehyde. They developed FOCMA antibody, reaching a peak titre of 256, and no virus could be cultured either from the vaccine preparations or from the tissues of the cats.
Collapse
|
21
|
Bennett AM, Sabine M. Viral leukaemia in domestic cats. Med J Aust 1975; 2:52, 54, 56 passim. [PMID: 169461 DOI: 10.5694/j.1326-5377.1975.tb95101.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
22
|
Rogerson P, Jarrett W, Mackey L. Epidemiological studies on feline leukaemia virus infection. I. A serological survey in urban cats. Int J Cancer 1975; 15:781-5. [PMID: 166947 DOI: 10.1002/ijc.2910150509] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
A survey of the incidence of feline leukaemia virus (FeLV) infection in cats in a large urban area was made by studying the prevalence of antibodies to feline leukaemia virus-associated cell membrane antigens. Two serological tests were used, immunofluorescence and a mixed immunoglobulin rosette technique. The overall incidence of cats with antibodies was 40%, contrasting with 6% in the surrounding rural area. Only 6% of urban kittens were positive while 50% of adults had antibodies. The incidence in adults rose from 29% at 5-6 months to 74% in cats over 3 years. Stray cats had an incidence twice as high as that of domestic pets. These results support and extend earlier findings that FeLV infection is common and is horizontally transmitted.
Collapse
|
23
|
Lawler SD. Letter: Chromosomes and malignancy. Lancet 1975; 1:1083-4. [PMID: 48745 DOI: 10.1016/s0140-6736(75)91847-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
24
|
Parker JE. Letter: Epidemiology of leukaemia. Lancet 1975; 1:1083. [PMID: 48744 DOI: 10.1016/s0140-6736(75)91846-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
25
|
MESH Headings
- Anemia/etiology
- Animals
- Antibodies, Viral/analysis
- Antigens, Viral/analysis
- Cat Diseases/epidemiology
- Cat Diseases/genetics
- Cat Diseases/transmission
- Cats/microbiology
- Cell Transformation, Neoplastic
- Cells, Cultured
- DNA, Viral
- Disease Outbreaks
- Female
- Fibrosarcoma/etiology
- Fibrosarcoma/immunology
- Fibrosarcoma/transmission
- Glycoproteins/metabolism
- Leukemia/genetics
- Leukemia/transmission
- Leukemia Virus, Feline/immunology
- Leukemia Virus, Feline/metabolism
- Leukemia Virus, Feline/ultrastructure
- Leukemia, Experimental/etiology
- Leukemia, Experimental/immunology
- Leukemia, Experimental/pathology
- Maternal-Fetal Exchange
- Neoplasms, Experimental/etiology
- Oncogenic Viruses/immunology
- Oncogenic Viruses/ultrastructure
- Pregnancy
- RNA, Viral/metabolism
- Sarcoma Viruses, Feline/ultrastructure
- Tumor Virus Infections/epidemiology
- Viral Proteins/metabolism
- Virus Replication
Collapse
|